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Abstract
The trace element zinc is essential for the immune system, and zinc deficiency affects multiple
aspects of innate and adaptive immunity. There are remarkable parallels in the immunological
changes during aging and zinc deficiency, including a reduction in the activity of the thymus and
thymic hormones, a shift of the T helper cell balance toward T helper type 2 cells, decreased
response to vaccination, and impaired functions of innate immune cells. Many studies confirm a
decline of zinc levels with age. Most of these studies do not classify the majority of elderly as zinc
deficient, but even marginal zinc deprivation can affect immune function. Consequently, oral zinc
supplementation demonstrates the potential to improve immunity and efficiently downregulates
chronic inflammatory responses in the elderly. These data indicate that a wide prevalence of
marginal zinc deficiency in elderly people may contribute to immunosenescence.
Review
Introduction
The human body contains 2–3 g zinc, most of which is
bound to proteins. Over 300 enzymes have been shown
to contain zinc, either directly involved in catalysis, as a
cofactor, or for structural stabilization [1]. Another large
group of zinc containing proteins are transcription factors,
many of which contain zinc fingers and similar structural
motives. From in silico studies searching for known zinc-
binding patterns, it has been estimated that approxi-
mately 10% of the human genome encode for proteins
that could bind zinc [2].
Severe zinc deficiency is characterized by growth retarda-
tion, skin lesions and impaired wound healing, hypogo-
nadism, anemia, diarrhea, anorexia, mental retardation,
and impaired visual and immunological function [3,4].
Notably, also during milder forms of zinc deficiency an
effect on immunity is observed.
On the cellular level, zinc is essential for proliferation and
differentiation, but zinc homeostasis is also involved in
signal transduction [5,6] and apoptosis [7]. Cells depend
on a regular supply of zinc and make use of a complex
homeostatic regulation by many proteins [8], but the
plasma pool, which is required for the distribution of
zinc, represents less than one percent of the total body
content [1]. Despite its important function, the body has
only limited zinc stores that are easily depleted and can
not compensate longer periods of zinc deficiency. Addi-
tionally, during infections pro-inflammatory cytokines
mediate changes in hepatic zinc homeostasis, leading to
sequestration of zinc into liver cells and subsequently to
hypozincemia [9]. Alterations in zinc uptake, retention,
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ciency and affect zinc-dependent functions in virtually all
tissues, and in particular in the immune system.
Role of zinc in the immune system
The trace element zinc is essential for growth and develop-
ment of all organisms and the high rate of proliferation
and differentiation of immune cells necessitates a con-
stant supply with sufficient amounts of zinc. In the fol-
lowing section, we will discuss the different roles of zinc
in the immune system.
In a review by Beisel, the effects of zinc deficiency on
immunity in animal models are summarized [10]. The
effects are hypoplasia of lymphoid tissues, and reductions
in T-helper cell numbers, NK cell activity, antibody pro-
duction, cell mediated immunity, and phagocytosis [10].
In humans, the most prominent example for the effects of
zinc deficiency is acrodermatitis enteropathica, a rare auto-
somal recessive inheritable disease that causes thymic
atrophy and a high susceptibility to bacterial, fungal, and
viral infections [11]. It is a zinc-specific malabsorption
syndrome based on a mutation within the gene for the
intestinal zinc transport protein hZip4 [12,13]. All symp-
toms can be reversed by nutritional supplementation of
excess zinc. Zinc deficiency does not affect just a single
component of the immune system; the effects are com-
plex, occur on many levels, and involve the expression of
several hundred genes [14,15]. Short term effects include
the regulation of the biological activity of thymulin by the
plasma zinc status, while long term effects can lead to
changes in immune cell subpopulations [16]. Even epige-
netic effects were observed [17]. Gestational zinc defi-
ciency in mice not only depressed the immune function of
the offspring of these mice, but to a lesser extent compro-
mised immune function was still found in the second and
third filial generation, even though these mice had been
fed with a zinc sufficient diet [17].
One major mechanism by which zinc affects immunity is
its role as a signaling ion (figure 1). The intracellular con-
centration of free zinc is regulated by three mechanisms.
One is transport through the plasma membrane [5].
Another mechanism involves storage in and release from
vesicles, so-called zincosomes, in which zinc is stored as a
complex with multiple ligands [18]. Finally, zinc binds to
metallothionein (MT). Through its 7 binding sites with
different affinities, MT buffers zinc in the pico- to
nanomolar range, and can additionally be controlled by
release of zinc by oxidation of zinc-binding cysteine thiol
residues [19].
Zinc signals, i.e. changes in the intracellular concentration
of free zinc mediated by these three mechanisms, act on
immune cell signal transduction [20]. The first example
was protein kinase C (PKC), which has been identified as
a molecular interaction partner for zinc in T cells [21]. Its
N-terminal regulatory domain contains four Cys3His zinc
binding motifs. Zinc treatment stimulates PKC kinase
activity, its affinity to phorbol esters, and binding to the
plasma membrane and cytoskeleton. Furthermore, zinc
chelators inhibit the induction of these events by physio-
logical activators of PKC [20].
The lymphocyte protein tyrosine kinase (Lck), a Src-fam-
ily tyrosine kinase, is an example for a different mecha-
nism by which zinc acts on signal transduction. Zinc ions
promote activation of Lck and its recruitment to the T cell
receptor complex by linking two protein interface sites.
The N-terminal region of Lck is recruited to the intracellu-
lar domains of the membrane proteins CD4 or CD8 by a
'zinc clasp' structure [22-24]. At the second zinc-depend-
ent interface site two zinc ions at the dimer interface of the
SH3 domains stabilize homodimerization of Lck, which is
thought to promote autophosphorylation required for its
activation [25].
Zinc signals were also observed when monocytes were
treated with lipopolysaccharide. These zinc signals regu-
late inflammatory signaling [26]. Here, cyclic nucleotide
phosphodiesterases and MAPK phosphatases were identi-
fied as molecular targets of zinc [26-28]. Signaling via the
transcription factor NF-κB is also dependent on zinc sig-
nals; however, in this case it is no direct interaction with
zinc, but rather a regulation of upstream signaling path-
ways leading to the activation of NF-κB [26].
Recent papers demonstrate an influence of zinc transport-
ers on signal transduction. Zrt/Irt-like protein (ZIP)7
releases Zn from the ER, controlling tyrosine phosphor-
ylation [29], and lysosomal ZIP8 is required for zinc-
mediated calcineurin inhibition and interferon (IFN)-γ
expression in T cells [30]. Conversely, there also exist feed-
back mechanisms, which act on zinc homeostasis. The
promoters of MT and of several zinc transporters are
under the control of the metal-response element binding
transcription factor (MTF)-1. In contrast to other tran-
scription factors with zinc fingers that bind zinc constitu-
tively, its DNA-binding is regulated by the stabilization of
zinc finger motifs by free cellular zinc [5,31,32].
Zinc deficiency in the elderly may impair zinc-dependent
signaling, and thereby immune function. In one recently
published study, peripheral blood mononuclear cells
(PBMC) from zinc-deficient elderly showed impaired NF-
κB activation and interleukin (IL)-2 production in
response to stimulation with PHA, which was corrected by
in vivo supplementation of zinc (45 mg/day as gluconate)Page 2 of 17
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[33], indicating a link between zinc deficiency and the
effect of zinc on NF-κB signaling.
Zinc and innate immunity
Zinc supplementation in vitro can trigger events required
for the recruitment of leukocytes to the site of infection.
For example, high zinc concentrations induce chemotaxis
of polymorphonuclear cells [34], and zinc promotes the
adhesion of myelomonocytic cells [35]. On the other
hand, zinc deficiency in vivo causes impaired phagocyto-
sis, parasite killing, and oxidative burst of monocytes and
neutrophil granulocytes, and a decrease in NK cell activity
[36-38]. Zinc is also required for recognition of HLA-C
molecules by the killer cell inhibitory receptors on NK
cells, but, notably, zinc is only necessary for inhibitory,
but not stimulatory effects [39]. Via this mechanism, zinc
deficiency may promote nonspecific killing by NK cells.
However, this effect is counteracted by a reduction of NK
cell lytic activity in zinc deficient patients [40].
Zinc and adaptive immunity
The adaptive immune response is based on two groups of
lymphocytes: B cells, which differentiate into immu-
noglobulin secreting plasma cells and hereby induce
humoral immunity, and T cells, which mediate cytotoxic
Zinc as a signal molecule for immune cellsF gure 1
Zinc as a signal molecule for immune cells. Zinc homeostasis is tightly controlled by three mechanisms: (A) Transport 
through the plasma membrane by zinc transporters from the ZnT (SLC A30) or ZIP (SLC A39) families. (B) Buffering by metal-
lothionein. (C) Reversible transport by ZnT and ZIP proteins into or out of zincosomes, and storage bound to ligands that 
form a zinc sink. Zinc signals, i.e., changes in the intracellular concentration of free zinc, control immune cell signal transduction 
by regulating the activity of major signaling molecules, including kinases, phosphatases, and transcription factors. One repre-
sentative example for each group is given. (TCR, T cell receptor; MKP, MAPK phosphatase; MTF-1, metal-response element 
binding transcription factor-1).Page 3 of 17
(page number not for citation purposes)
Immunity & Ageing 2009, 6:9 http://www.immunityageing.com/content/6/1/9effects and helper cell functions of cell mediated immu-
nity. Both responses depend on the clonal expansion of
cells after recognition of their specific antigen. While B
cells depend on zinc for proliferation, they do so to a
lesser extent than T cells [41,42]. In addition, a height-
ened level of apoptosis in pre B and T cells was found in
zinc deficient mice. Mature cells are more resistant to
apoptosis induced by zinc deficiency, possibly because of
the higher level of the anti-apoptotic protein BCL-2 in
these cells [16]. Not only does zinc deficiency affect B cell
lymphopoiesis, it has also been shown to lead to a reduc-
tion in antibody-mediated immune defense [16].
The most prominent effect of zinc deficiency is a decline
in T cell function, which results from multiple causes.
Thymulin, a hormone secreted by thymic epithelial cells,
requires zinc as a cofactor and exists in the plasma in two
forms, a zinc-bound active one, and a zinc-free, inactive
form. It is essential for differentiation and function of T
cells, which could explain some of the effects of zinc defi-
ciency on T cell function. In mice, zinc deprivation
reduces the level of biologically active thymulin in the cir-
culation [43]. This effect has been observed in the absence
of thymic atrophy, and thymulin activity was restored
after in vitro supplementation of the serum with zinc, indi-
cating that thymulin activity is directly dependent on
serum zinc [44]. In mildly zinc deficient humans, thymu-
lin activity was also decreased, and a comparable effect of
zinc supplementation in vitro and in vivo was described
[45].
Furthermore, the TH1/TH2 balance is affected by zinc.
During zinc deficiency, the production of TH1 cytokines,
in particular IFN-γ, IL-2, and tumor necrosis factor (TNF)-
α is reduced, whereas the levels of the TH2 cytokines IL-4,
IL-6, and IL-10 were not affected in cell culture models
[46] and in vivo [47,48]. In addition to the immunomod-
ulatory effects of zinc deprivation, zinc supplementation
can modulate T cell dependent immune reactions. Zinc
supplementation to PBMC leads to T cell activation, an
indirect effect that is mediated by cytokine production by
other immune cells, but higher concentrations of zinc can
also directly suppress T cell function. Here, zinc reduces
IL-1 dependent T-cell stimulation by inhibiting the inter-
leukin-1 receptor associated kinase-1 [49]. In vitro, zinc
inhibits the mixed lymphocyte culture (MLC) [50], and a
clear reduction in the MLC was also shown in PBMC from
human subjects that had been supplemented with 80 mg
zinc per day for one week. Notably, the response to a
recall antigen, tetanus toxoid, was unaffected in these cells
and zinc specifically inhibited the allogenic reaction [51].
Zinc and cytokine levels
Zinc has been characterized as a positive and negative reg-
ulator of pro-inflammatory cytokines, in particular IL-1
and TNF-α. Some reports describe that zinc supplementa-
tion to human peripheral blood mononuclear cells leads
to an increased mRNA production and release of the
monokines IL-6, IL-1β, and TNF-α, and a combination of
nonstimulatory concentrations of LPS and zinc results in
the production of large amounts of monokines [52]. On
the other hand, several reports indicate that zinc treat-
ment suppresses the formation of pro-inflammatory
cytokines [46,53]. This difference can be explained by the
observation that the effect of zinc is concentration
dependent, and that zinc can be stimulatory or inhibitory
in the same experimental system. Whereas an increase of
intracellular free zinc, which can be imitated by moderate
zinc supplementation to cell cultures, is a zinc signal
involved in cytokine production of monocytes in
response to LPS [26], higher concentrations can have an
antagonistic effect by inhibition of cyclic nucleotide phos-
phodiesterases and a subsequent activation of protein
kinase A [27,28]. In T cells, cytokine secretion is only indi-
rectly affected by zinc. Zinc-induced release of IFN-γ and
the soluble IL-2 receptor depends on the presence of
monocytes, and is based on direct cell to cell contact and
zinc-mediated production of the monokines IL-1 and IL-
6 [52].
Immunological changes during aging
Aging of the immune system, also referred to as immu-
nosenescence, describes the age-related changes in
immune function that lead to increased susceptibility of
older people to infectious diseases, autoimmunity, and
cancer. The capacity of the immune system to mount an
adequate response decreases with age, starting around 60,
but several factors such as lifestyle and underlying dis-
eases can significantly affect the onset in each individual
[54]. Interestingly, a comparison between alterations of
the immune system during zinc deprivation and aging
shows many similarities, indicating a possible relation
between immunosenescence and zinc deficiency [55]. In
both cases it comes to anergy, thymic atrophy, and
reduced NK cell activity, cell mediated cytotoxicity, helper
T cell activity and thymulin levels [56].
As it could be expected from the decline in immune func-
tion, aged patients suffer from an augmented incidence
and mortality of infectious diseases such as pneumonia
[57] and tuberculosis [58], and re-infections with herpes
zoster increase [59]. The frequency of autoimmune dis-
eases is augmented with age, too, accompanied by an
increase in autoantibodies, which is, interestingly, not
observed in centenarians [60,61]. On the other hand, spe-
cific IgE production decreases, reducing the risk for aller-
gies [62,63].
Cancer is a disease that occurs over proportion in elderly
as well. People ≥65 years have an eleven fold higher inci-Page 4 of 17
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younger subjects [64]. Although the immune system func-
tions as a network in which nearly all elements interact
with each other, some components can be identified that
are especially affected by aging and whose functional
impairment causes increased susceptibility for diseases
like the examples mentioned above [65,66].
Neutrophil granulocytes form the first line of defense
against pathogens, mainly by phagocytosis, but also
cytokine secretion and recruitment of other immune cells.
The higher incidence of microbial infections in the eld-
erly, although often attributed primarily to a decline in T
cell function, may also in part be the result of an impair-
ment of neutrophils. The total number of neutrophils is
not different in the aged compared to younger controls.
However, phagocytosis, oxidative burst, and intracellular
killing are affected and neutrophils from the elderly show
a reduction in chemotaxis and a reduced resistance toward
apoptosis, based on a diminished antiapoptotic effect of
stimuli such as LPS, G-CSF, and GM-CSF [67].
While the activity of all other immune cells decreases with
age, some functions of macrophages, and their precursors
monocytes, are even augmented in elderly. No change in
the number of monocytes in the blood is observed and, in
contrast to neutrophils, chemotaxis, phagocytosis, and
oxidative burst remain unchanged [68]. However, their
accessory function for T cells is impaired, although the
expression of several cytokines, adhesion molecules, and
HLA-DR is not altered [69]. The plasma concentrations of
IL-6, IL-8, MCP-1, MIP-1α, and TNF-α are positively cor-
related with age [70]. Furthermore, production of pro-
inflammatory cytokines such as IL-1, IL-6, IL-8, and TNF-
α after stimulation with LPS is significantly increased
[71,72]. In contrast, IFN-α, which is mainly produced by
monocytes, is reduced [73]. The other major group of
antigen presenting cells, dendritic cells, seem to be unaf-
fected by age with respect to surface marker expression
and transendothelial migration [74]. The total number of
NK cells and their percentage among circulating cells is
increased in old people, but this effect is compensated by
a reduced cytotoxic activity on a per-cell basis and reduced
proliferation in response to IL-2 [75-77], together with
reduced calcium signaling and CD69 expression, while
TNF-α secretion remains unaffected [78]. Because the
main functions of NK cells are the elimination of cancer
or virus infected cells, the higher incidence of viral infec-
tions and cancer in the elderly may well be related to
impairment of NK cell function.
The most severe changes during aging are found in the
adaptive immune system. Aging leads to a shift in B cell
populations and antibody production. B cell numbers
decline with age and one would expect that this is accom-
panied by a decrease in immunoglobulins, but the oppo-
site has been observed, showing an increase of IgA and
several IgG subclasses [79]. The response to vaccination
with several antigens is diminished, which may result
from an impaired interaction with T helper cells (see
below), but also a loss of antibody affinity was found. At
the same time an increase in organ-specific and non-
organ-specific autoantibodies was observed, but, whereas
the latter increase with age, subjects over 90 years show
lower levels of organ-specific autoantibodies than
younger elderly [80]. Another change that occurs with age
is increased clonal expansion of B cells, which may be
connected to the increased incidence of lymphocyte
malignancies with age [80]. The effects of aging on B cells
and humoral immunity are summarized in figure 2.
Similar to the effects of zinc deficiency, the main changes
of aging also affect the T cell system. T cells from elderly
subjects show decreased proliferation in response to T cell
receptor (TCR) stimulation or mitogens [81], an altered
CD4/CD8 ratio, and higher expression of CD95 and the
pro-apoptotic BAX combined with a decrease in BCL-2
and p53, which leads to increased apoptosis [82]. A prom-
inent feature of immunosenescence is thymic involution.
This leads to a decrease in the generation of new T cells,
finally resulting in a lower number of naïve (CD45RA+)
and a higher number of memory (CD45R0+) T cells [83].
Zinc deficiency can also cause thymic involution, regard-
less of age. A reduction of zinc availability induces higher
levels of thymocyte apoptosis, either by elevating gluco-
corticoid production or because zinc has a negative regu-
latory function in immune cell apoptosis [16,20,84].
Notably, supplementation of the drinking water of old
mice with zinc sulfate has been reported to induce an
increase in thymic mass [85], and parameters such as
thymic weight, the number of viable thymocytes, and
serum thymulin activity were restored by oral zinc supple-
mentation [86]. Hence, lower zinc levels in the elderly
could contribute to thymic involution by augmenting
apoptosis during T cell maturation and selection in the
thymus.
As in B cells, monoclonal expansion has been found for T
cells from elderly subjects. The expanded subsets can
make up a large fraction of T cells, but no signs of malig-
nant transformation have been reported [87]. The
expanded subsets were primarily CD8 positive whereas
CD4 populations remained unchanged. However, T
helper cells are also affected by aging, showing a decreased
TH2/TH1 ratio in the elderly, measured by CCR4/CCR5
surface expression [88]. In addition, alterations in the bal-
ance of TH1/TH2 cytokines occur that are similar to the
effects observed during zinc deprivation [88]. The TH1
cytokines IFN-γ, IL-2, and sIL-2R are reduced. In contrast,Page 5 of 17
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shift toward TH2 cytokines [89,90].
Decreased humoral immunity may not only result from
changes in B cells, but in part be caused by a disturbance
of T cell help and alterations of cytokine levels, because
many cytokines that control B cell functions are affected
by aging [90,91]. As summarized in figure 3, a disturbed
humoral response may be the result of a combination of
an impaired interaction between antigen presenting cells
(APC) and T helper cells and a shift in the TH1/TH2 bal-
ance, which both add to the immunological alterations
that occur directly in B cells. It is noteworthy that zinc can
antagonize all these effects: Zinc supplementation can
suppress the release of pro-inflammatory cytokines from
LPS-stimulated monocytes [27], and addition of zinc to
PBMC promotes IFN-γ release [92]. In vitro zinc supple-
mentation can also decrease IL-10 release [93] and restore
IFN-α production from leukocytes of elderly subjects [73].
However, the effect of zinc is not limited to cytokine
expression, because the antiviral activity of IFN-α, but not
IFN-β and -γ, is potentiated by addition of zinc in vitro
[94].
Zinc status of the elderly
Many micronutrients affect immunity and suboptimal
nutritional supply can cause an impaired immune
response [95]. This is especially true for zinc, given its
essential role in many immunological processes, as
described above. In many elderly, the required supply of
zinc is not met [96]. A multitude of influencing factors has
been suggested, which include physiological, social, psy-
chological, and economic factors. For example, reduced
mobility leads to a decrease in energy requirements. The
resulting consumption of smaller quantities of food also
means consuming lower amounts of trace elements,
including zinc. In addition, decreased intestinal absorp-
tion, which in part depends on the composition of the
food, and medication like diuretics, could cause a nega-
tive zinc balance, even if there is sufficient uptake. All
these factors together can result in insufficient nutritional
supply with trace metals in the elderly [4]. Finally, some
diseases that occur with increased frequency in older peo-
ple, such as diabetes, are also accompanied by zinc defi-
ciency [4,97,98].
The recommended daily allowance (RDA) for zinc in indi-
viduals 19 years and older (special recommendations for
elderly do not exist) in the United States is 11 mg/day for
men and 8 mg/day for women [98]. An uptake below the
RDA can only be seen as an indicator of potential zinc
deficiency, because many other factors also play a role and
the possibility exists that the metabolism may adapt to
decreased zinc intake. Hence, it is necessary to analyze the
Disturbed B-cell function in ageingFigure 2
Disturbed B-cell function in ageing. In general, the numbers of B cells and specific antibodies (e.g., in response to vaccina-
tion) decrease with age, while total and unspecific immunoglobulin and autoantibodies increase. Some B cell clones expand, 
resulting in higher probability for lymphocyte malignancies.Page 6 of 17
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often serum or plasma zinc. However, this is not an ideal
parameter for determining the zinc status. When zinc defi-
ciency was experimentally induced in young subjects, they
showed significant effects on the production of IFN-γ, IL-
2, and TNF-α with an imbalance in the TH1/TH2 system,
but plasma zinc was not significantly affected [47].
Whereas reduced plasma or serum zinc levels can indicate
zinc deficiency, such deficiency can also occur at levels
that are within the reference values [98]. Possibly, other
parameters, such as labile intracellular zinc in leukocytes,
will be a more accurate measure for the zinc status in the
future [99].
Many studies about zinc nutrition and status in the elderly
exist (table 1). In most of these studies, zinc deficiency is
defined as a serum or plasma concentration below 10.7
μM, which corresponds to 70 μg/dL. In most cases a clear
tendency toward suboptimal zinc intake and decreasing
zinc plasma and serum levels with age were found, but
values were still within the reference range of 70 – 110 μg/
dL. An early study in 1971 investigated the correlation
between age and plasma zinc in 204 male subjects
between the ages of 20 to 84, and 54 female subjects
between 20 and 58, finding a significant linear decrease of
plasma zinc with age in both groups [100]. In contrast, red
blood cell zinc content was even slightly increased,
although these effects were not significant [100]. A signif-
icant reduction in serum zinc was also found for the 'old-
est old' (≥ 90 years), compared to healthy elderly between
65 and 89 years and adults between 20 to 64 years [101].
Three other studies did also not find a high prevalence of
zinc deficiency in the elderly, but while not being defi-
cient, in one study mean plasma levels were low (<85 μg/
dL) [102], in another serum zinc levels were significantly
below a young control group [89], and erythrocyte zinc
concentration was lower in 70–85 year olds, compared to
a group between 55 and 70 years [103].
Influence of zinc on age-related changes of immune functionFigure 3
Influence of zinc on age-related changes of immune function. Aging leads to an increase in pro-inflammatory cytokines 
and modulates the TH1–TH2 balance toward a TH2 response by reducing the TH-1 cytokines IFN-α and -γ and increasing IL-
10. This reduces T cell help for immunoglobulin class switch and causes unspecific activation of B cells. Zinc counteracts the 
effects on [a] pro-inflammatory cytokines [27], [b] IFN-α [73], [c] IFN-γ [92], and [d] IL-10 [93].Page 7 of 17
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Subjects Zinc status Reference
204 males, 20 – 84 y.
54 females, 20 – 58 y.
significant decrease of plasma zinc, but not erythrocyte zinc, with age [100]
146 elderly, 65–95 y. mean plasma levels below 85 μg/dL (= 13 μM) [102]
121 elderly, 60–97 y. Average zinc intake 7.3 mg/day, 6% had serum zinc under 70 μg/dL (= 10.7 μM) [132]
24 healthy, 69–85 y.
50 controls, 21–64 y.
reduced plasma zinc compared to young controls [106]
20 chronically ill elderly, 70–85 y. compared to Bunker et al. 1984 no effect on plasma and whole blood zinc, but reduction of 
leukocyte zinc
[107]
100 elderly, 60–89 y. 14.7% zinc deficient (<10.7 μM, plasma), >90% had intake below RDA (15 mg/ml in 1987) [123]
23 elderly, 65–85 y.
13 controls, 23–45 y.
IL-2 production was lower in elderly with reduced leukocyte and neutrophil zinc [126]
232 hospitalized, 60–104 y.
25 free living, 69–94 y.
serum and leukocyte zinc lower in hospitalized subjects [122]
53 healthy elderly, 64–95 y. serum zinc decreases with age, mean serum zinc within normal range, 65% had intake less than 2/
3 RDA
[105]
19 healthy, 51.3 m.a.
25 healthy, 77.7 m.a.
30 hospitalized, 80.8 m.a.
34 w/ulcers, 81.3 m.a.
plasma zinc negatively correlated with age, plasma and leukocyte zinc lower in hospitalized elderly 
compared to both healthy control groups
[121]
30 patients, 72–98 y.
12 healthy, 75–86 y.
23 controls, 18–55 y.
plasma zinc significantly decreased in both groups of elderly, zinc is lowered in 
polymorphonuclear but not mononuclear cells of elderly patients
[116]
118 subjects, 50–80 y. decrease in lymphocyte and granulocyte zinc, ~30% defined as zinc deficient [115]
21 elderly, 70–90 y.
20 young, 20–35 y.
significantly lower serum zinc in the elderly [89]
81 hospitalized, 65–102 y. 61% of subjects zinc deficient (<10.7 μM) [119]
345 elderly, > 70 y. 19% had hypozincemia (<12.2 μM), values of nursing home residents significantly lower than free 
living
[117]
29,103 subjects, NHANES III 42.5% of ≥71 y. had adequate zinc intake [108]
62 healthy, 90–106 y. zinc deficiency in 52% male and 41% female subjects, based on a reference range established in 
20–64 y. controls
[112]
44 oldest old, 90–107 y.
44 elderly, 65–89 y.
44 young, 20–64 y.
serum zinc significantly reduced in oldest old compared to elderly and young [101]
50 hospitalized, 83.5 m.a. 28% deficient (<10.7 μM serum zinc) [118]
13,463 subjects, NHANES II Correlation between serum zinc and age, decline starts at age 25 [104]Page 8 of 17
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ond National Health and Nutrition Examination Survey
(NHANES). In its course, over 13,400 serum samples were
analyzed for their zinc content. Serum zinc levels
increased into the third decade, and declined from there
[104]. In combination with an age-dependent decrease of
serum zinc, insufficient nutrition and low zinc intake
were described, but again mean serum zinc was still in the
normal range [105]. In another study, a significant differ-
ence between plasma zinc of healthy elderly and a young
control group has been found and the average daily intake
of healthy elderly was only 60% of the RDA [106], and
even significantly lower in housebound chronically ill
(39% RDA) [107]. This study describes no difference
between plasma and whole blood zinc contents between
healthy and chronically ill elderly people, but a significant
reduction of leukocyte zinc [106,107]. The third NHANES
has demonstrated in a large study population that inade-
quate zinc intake is frequent in American elderly [108],
and similar observations are reported from other regions
of the world, as well. The incidence of zinc deficiency also
increases with age in the Japanese [109]. Furthermore, the
European Nutrition and Health Report summarizes data
regarding the nutritional zinc uptake in elderly from Aus-
tria, Denmark, Germany, Hungary, and the UK. Zinc sup-
ply decreases with age, although it can be generally
regarded as sufficient. Furthermore, there is considerable
variation between countries, and zinc uptake is particu-
larly low in UK elderly [110].
Centenarians are a remarkable subgroup of the elderly,
who have achieved 'successful aging', without suffering
from age-related diseases [111]. Due to its beneficial effect
on immunity and healthy aging, measuring the zinc status
of these individuals seems indicated to investigate the
potential contribution of a difference in zinc homeostasis
to the greater health of centenarians. However, it was
shown that healthy nonagenarians and centenarians have
a high prevalence of zinc deficiency [112]. It still remains
to be seen if the decrease of zinc levels reaches a constant
level at a certain age, or if the decline continues after the
eight decade of life. In one study, measurements showed
a reduction in healthy 65–80 year old compared to the
zinc status of young adults, but no further reduction in
nonagenarians/centenarians [113]. In contrast, a compar-
ison of serum zinc between subjects younger than 65
years, compared to ones aged 65–89 years, and to subjects
≥ 90 years showed a significant decrease between the old-
est old an the other two groups indicating a continuing
reduction [101].
These data indicate that improved immune efficiency that
promotes successful aging in centenarians is not based on
a difference in their zinc status, but act via an unrelated
mechanism. This is in accordance with the observation
that parameters that are associated with reduced zinc lev-
els, e.g., increased production of pro-inflammatory
cytokines, are still observed in centenarians [111].
Whereas it is a general finding that plasma and serum zinc
decrease with age, few studies find a high frequency of
zinc deficiency in the elderly. In one study, subjects 90
years and older were zinc deficient compared to reference
data that the same laboratory had measured in younger
individuals [112]. In 67 south African elderly with a mean
age of 71.7 years, mean serum concentration was 61.8 μg/
dL, with 76.3% of the study population being zinc defi-
cient (<70 μg/dL) [114]. Another group found that only
42.9 percent of the elderly subjects that were investigated
had a sufficient intake of zinc (>67% RDA) [115]. How-
ever, it has to be noted that in this and several other older
studies higher RDAs of 15 mg (male) and 12 mg (female)
were used. Even with the current, lower RDAs zinc defi-
ciency would be frequent in the studied population, and
10 oldest old, 93–102 y.
15 old, 65–80 y.
15 young, 20–40 y.
10 infected, 63–75 y.
Significantly lower zinc in both groups of older subjects compared to younger ones, no decrease 
from old to oldest old
Lowest levels found in infected patients
[113]
101 elderly, 56–83 y. 35% zinc deficient (<90 μg/dL plasma zinc) [33]
668 hospitalized, 80.4 m.a.
105 healthy, 80.9 m.a.
20.2% zinc deficient (<70 μg/dL (or 10.7 μM) serum zinc) in the hospitalized, none in the healthy 
controls
[120]
188 aged, 55–70 y.
199 older 70–85 y.
Erythrocyte zinc lower and urinary zinc higher in the older participants. Less than 5% had 
insufficient zinc uptake (< 2/3 RDA)
[103]
93 healthy elderly, 55–70 y. Average of 13.0 μM serum zinc [134,139]
67 elderly, 71.7 m.a. Mean serum zinc 61.8 μg/dL (= 9.4 μM), 76.3% zinc deficient (<70 μg/dL or 10.7 μM) [114]
NHANES: National Health and Nutrition Examination Surveys, RDA: Recommended Daily Allowance, y.: years, m.a.: mean age
Table 1: Zinc status of the elderly.  (Continued)Page 9 of 17
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granulocyte and lymphocyte zinc content. Again, plasma
zinc did not indicate zinc deficiency in these subjects,
underscoring the difficulties with the use of this parameter
[115].
The considerable variability in the classification of elderly
people as zinc deficient, either according to their intake or
measured zinc status, is caused by more than the use of
different RDA, different parameters to measure the zinc
status, or the use of different reference values to define
zinc deficiency. They can also result from a limited com-
parability of the populations that are investigated. In
addition to regional differences, which affect factors such
as food composition, health status and living conditions
have great influence. Many studies were performed with
healthy elderly. If zinc is as important for immune func-
tion as indicated above, this group is the most likely to
have normal zinc values. Hence, a difference is likely to
exist between apparently healthy, free living elderly and
institutionalized subjects, and this has already been
described in studies that directly compare these groups
[116,117]. Accordingly, a high prevalence of zinc defi-
ciency was found in 50 hospitalized elderly patients, 28%
of which were zinc deficient (<10.7 μM plasma zinc)
[118], another group of 81 hospitalized subjects (65–102
years) whose mean serum zinc was below 10.7 μM, and
61% of which were zinc deficient [119], or in a study
where 20.2% of hospitalized elderly (≥70 y.) had serum
zinc below 70 μg/dL, while a healthy control group
included no zinc deficient subjects [120].
Some authors speculate that insufficient intake or low
zinc content in hospital diets may be responsible for the
reduced zinc levels found in sick, and especially in hospi-
talized patients [121]. A negative overall zinc balance in
housebound chronically ill patients was documented by a
detailed metabolic balance study, in which an average
intake of only 39% of the RDA was found [107]. However,
in another study hospitalized elderly had reduced serum
and leukocyte zinc levels compared to a free living control
group of similar mean age, although their mean dietary
intake of zinc did not vary significantly [122].
Independent from the classification of elderly as zinc defi-
cient, correlations between zinc status and immunologi-
cal parameters have been observed, indicating that even
marginal zinc deficiency can affect immunity, while the
zinc status is still within the reference values. A study by
Bogden and coworkers demonstrates a positive correla-
tion between plasma zinc concentration and delayed cuta-
neous response to skin antigens [123]. Hereby, even small
differences of only 1.5 μM seemed to affect skin test
anergy. In elderly hemodialysis patients, a correlation
between Diphtheria vaccination and zinc status was
described. Compared to age-matched controls, the group
of patients who did not respond to vaccination had
reduced serum zinc levels (p < 0.004), whereas the levels
of responders were not significantly decreased [124].
Proliferation and cytokine secretion in response to stimu-
lation with PHA were analyzed in lymphocytes isolated
from healthy elderly (70–85 y.) subjects with mean zinc
intake and serum and erythrocyte levels within the nor-
mal range. There was a positive trend for a correlation
between proliferation and serum zinc in male subjects.
Furthermore, the production of IL-10 in response to PHA
showed a negative correlation with erythrocyte zinc in
males, while baseline and PHA-stimulated production of
this cytokine were negatively correlated with serum zinc
in females [125].
Reduced IL-2 production upon stimulation with PHA was
observed in elderly subjects who had reduced levels of cel-
lular zinc in lymphocytes and neutrophils, whereas IL-2
production was not affected in zinc sufficient elderly and
younger controls [126]. In another study, subjects 90
years and older were not only zinc deficient, but a positive
correlation between serum zinc and percentage of NK
cells among leukocytes was established [112]. In a differ-
ent group of hospitalized patients, serum zinc was nega-
tively correlated to IgG2 levels. Additionally, zinc
deficient patients had significantly higher frequencies of
congestive cardiopathy, respiratory infections, gastroin-
testinal diseases, and depression [118].
A decline of zinc status with age has been established, and
a correlation between zinc status and immune function in
the elderly seems to exist. The question remains if zinc
deficiency is caused by infections that occur more fre-
quently in elderly people and lead to a subsequent loss of
zinc, or if aging poses a risk of becoming zinc deficient,
leading to immunosenescence and increased susceptibil-
ity to infectious diseases. In the latter case, zinc supple-
mentation could be a useful approach to improve the
immune status of elderly people.
Effect of zinc supplementation on elderly
Several studies have investigated the impact of zinc sup-
plementation on the immune defense [127], and some of
them focused on the investigation of the effect of zinc sup-
plementation on different immune parameters particu-
larly in elderly subjects. Their mean findings are
summarized in table 2. The results are difficult to compare
not only due to differences in the studied populations and
their zinc status, but also due to study design, the immu-
nological parameters that have been investigated, and
dosage, duration, and bioavailability of zinc supplemen-
tation.Page 10 of 17
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health. Zinc supplementation (45 mg elemental zinc as
gluconate vs. placebo) to a group of elderly significantly
reduced the incidence of infections during a one year
course [128]. In another group of elderly, supplemented
with a mixture of vitamins and minerals including zinc (7
mg per day, given as sulphate) for one year, the incidence
of pneumonia was significantly higher in individuals with
low (<70 μg/dL, corresponding to 30% of the study
group) serum zinc, compared to ones that were not zinc
deficient [129].
Multiple reports describe an effect of zinc on T cells of eld-
erly subjects. In one of the first studies investigating the
effect of zinc supplementation on the immune system,
healthy subjects over 70 years of age received 220 mg zinc
sulfate (corresponding to 50 mg of elemental zinc) twice
daily for one month, and were compared to a control
Table 2: Zinc supplementation studies in elderly. 
Subjects Number Intervention1 Effect Reference
institutionalized > 70 years 15 (C)
15 (Z)
100 mg zinc as sulfate
one month
increased T cell numbers, DTH, and 
response to tetanus vaccine compared to 
control group
[130]
anergic to DTH, 64–76 years 5 (Z) 55 mg zinc as sulfate
four weeks
improved DTH [132]
free-living, 60–89 years 36 (P)
36 (Z,15)
31(Z,100)
15 or 100 mg Zn as acetate
3 months
no effect on DTH or in vitro lymphocyte 
proliferation
[137]
zinc-deficient males, 65–78 years 8 (Z) 60 mg zinc
as acetate
4.5 months
increase in DTH after supplementation [131]
free-living, 60–89 years 24 (P)
20 (Z,15)
19(Z,100)
15 or 100 mg Zn as acetate
12 months
negative effect on DTH, NK cell activation 
only after 3 months
[138]
institutionalized, 73–106 years 44 (P)/(Z) crossover 20 mg zinc
as gluconate
8 weeks
increased thymulin activity [136]
zinc deficient, 50–80 years 13 (Z) 30 mg zinc
as gluconate
6 months
increase in plasma thymulin activity, IL-1, and 
DTH after supplementation
[115]
institutionalized, 64–100 years 190 (C)
160 (Z)
90 mg zinc as sulfate
60 days
no effect of zinc on response to influenza 
vaccination
[149]
institutionalized, ≥ 65 years 30 (P)
28 (Z)
25 mg zinc
as sulfate
3 months
increase in CD4+DR+ T cells and cytotoxic 
T cells compared to placebo
[133]
free-living, 65–82 years 19 (Z) 10 mg zinc as aspartate
7 weeks
reduced levels of activated T helper cells and 
basal IL-6 release from PBMC, improved T 
cell response
[140,141]
institutionalized 25(P)
24(Z)
6(P)
6(Z)
45 mg as gluconate
12 months
45 mg as gluconate
6 months
reduced incidence of infections
increased IL-2 mRNA in response to ex vivo 
stimulation with PHA
[33,128]
healthy, 55–70 y. 31 (P)
28/34 (Z)
15/30 mg zinc as gluconate
6 months
no effect on markers of inflammation or 
immunity
[134]
1The values are given as elemental zinc
DTH: delayed type hypersensitivity reaction, (C) control group without supplementation, (P) placebo, (Z) zinc supplementationPage 11 of 17
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status was not assessed. Whereas the total number of cir-
culating lymphocytes was not affected, the proportion of
T cells was significantly increased, but this did not lead to
a change of the response to in vitro stimulation with T-cell
mitogens. An increased delayed type hypersensitivity
(DTH) reaction and response to vaccination with tetanus
toxiod was observed [130]. Three further studies con-
firmed the effect of zinc supplementation on DTH with
lower zinc doses, but all were performed with a low
number of participants and without a control group
[115,131,132]. Wagner et al. investigated 5 subjects that
were anergic to four different skin test antigens (Candida,
Trochophyton, mumps, tuberculin), and all five tested pos-
itive to at least one antigen after 4 weeks of supplementa-
tion with 55 mg zinc (as sulfate) per day [132]. Cossack
found in eight zinc deficient elderly males, who were clas-
sified as anergic to skin antigen tests, an improvement of
DTH after supplementation with 60 mg per day. This was
accompanied by an increase of plasma and cellular zinc
[131]. Prasad and coworkers investigated 13 zinc deficient
subjects whose plasma zinc levels and granulocyte and
lymphocyte content increased significantly after supple-
mentation with 30 mg zinc per day. They also found an
increase in the number of positive skin test reactions after
six months [115]. However, as no control groups have
been investigated in either study, it can not be excluded
that repeated testing may have contributed to the
improvement in DTH reactions.
A beneficial effect of zinc on T cell function has also been
observed when other parameters were investigated. A sig-
nificant increase in the numbers of cytotoxic T cells and
activated (HLA-DR positive) T helper cells was found in
residents of a retirement home who had been supple-
mented with zinc (25 mg per day) [133]. This raise in
HLA-DR positive cells seems to result from increased total
T cell numbers, while the percentage of activated cells
within the T cell population remains constant [133,134].
Fabris et al. have found decreased plasma zinc with age
and an age-dependent decrease of plasma thymulin activ-
ity. Because thymulin activity was restored by in vitro addi-
tion of zinc, the effect was not caused by thymic
involution, rather was thymulin inactive due to decreased
plasma zinc [135]. This observation has been confirmed
in a later study with 44 institutionalized elderly, also
detecting a partial recovery of thymulin activity after in
vitro zinc supplementation. In the same study, a 16 week
crossover with 8 weeks of zinc supplementation (20 mg/
day) and 8 weeks of placebo caused an increase in serum
levels of active thymulin, but the effect was only signifi-
cant in lean subjects with a body mass index ≤21 [136]. In
another in vivo study with zinc deficient elderly subjects,
zinc supplementation also significantly increased serum
thymulin activity [115].
The results showing an improvement of T cell-dependent
reactions after zinc supplementation are not unchal-
lenged. In a well designed study, Bogden and coworkers
supplemented elderly subjects with zinc in three groups:
placebo, 15 mg zinc per day, and 100 mg zinc per day. To
prevent underlying effects of deficiencies in other micro-
nutrients, multivitamins and mineral supplements were
given to all participants. Baseline data at the beginning of
the study [123] as well as results after three months [137]
and after one year were reported [138]. After three
months, no significant effects were found in response to
either dose of zinc, neither on DTH, nor lymphocyte pro-
liferation to several antigens. Initially, zinc supplementa-
tion in subjects who are not zinc deficient may be
beneficial, but the effect could be only temporary, due to
adaptation to a higher zinc intake [137]. This assumption
is supported by the observation that NK cell activity
increased transiently after 3 months in the group receiving
100 mg zinc, but not after 6 or 12 months. After one year,
an increase in DTH was observed in all three groups. This
may have been caused by repeated testing, as discussed
above, or by a booster effect of the additional multivita-
min and mineral supplement that had been administered
to all participants. However, zinc supplementation in
both groups significantly diminished this effect. The dif-
ference between this study and the ones discussed above
could be due to the fact that this is the only one that used
a placebo group for comparison, or that zinc may interfere
with the beneficial effect of one of the other micronutri-
ents, or be a sign of adaptation to zinc supplementation
during the longer supplementation period. It has also to
be considered that no zinc deficiency was observed in
these subjects, which had a mean of approximately 13 μM
plasma zinc [138].
A six month, placebo controlled supplementation study
with 15 and 30 mg Zn per day (as gluconate) investigated
the long-term effects on the immune status of 93 healthy
Irish individuals between 55 and 70 years [139]. At base-
line, positive correlations between erythrocyte zinc and
the amount of T lymphocytes (CD3+), NKT cells (CD3+/
CD16+/CD56+), activated T cells (CD25+ HLA-DR+),
and naïve T cells (CD3+/CD45RA+) were observed. In
addition, erythrocyte zinc was inversely correlated with
granulocyte phagocytic capacity and serum zinc with the
concentration of CRP [134]. After receiving zinc, the par-
ticipants supplemented with 15 mg Zn/day had an
increased ratio of helper to cyctotoxic T cells, and after 3
months B cell numbers were lower in the 30 mg group
compared to the other two groups. Zinc supplementation
had no impact on a vast number of other parameters
investigated, including inflammation markers, granulo-
cyte phagocytosis, and cytokine production by mono-
cytes. The population investigated in this study had mean
serum zinc of 13 μM and thus no zinc deficiency at thePage 12 of 17
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nificant long-term effects of zinc supplementation on
most immune parameters [134,139].
Zinc supplementation does not just promote the immune
response; it rather normalizes immune function on the
cellular level. Compared to younger subjects, PBMC from
elderly have increased ex vivo generation of pro-inflamma-
tory cytokines, and normalized cytokine production was
observed after zinc supplementation [128,140]. In addi-
tion, zinc supplementation improves T cell function, caus-
ing reduced levels of unspecifically activated T cells [141],
and improved IL-2 mRNA expression and T cell response
to stimulation with mitogens [128,140]. This does not
indicate, however, that an effect of zinc supplementation
on cytokine production is limited to the elderly. Zinc sup-
plementation to younger subjects (19–31 years of age, 15
mg Zn per day as ZnSO4), resulted in increased mRNA
production of TNF-α and IL-1β in LPS-treated monocytes
and granulocytes, and augmented IFN-γ mRNA in T cells
treated with microbeads to simulate antigen presentation
[142].
The intake of zinc was positively correlated with the
results of tests for cognitive performance in 260 subjects
between 65 and 90 years [143]. Another study reported a
negative correlation between zinc status and indicators for
stress and depression and a positive correlation with the
mental capacity in elderly from different European coun-
tries [144], but this was not confirmed in an investigation
of 387 participants between 55 and 87 years who had
been supplemented either with placebo, 15, or 30 mg ele-
mental zinc per day (as gluconate) for 6 months [145].
Here, despite significant changes in serum zinc, almost no
significant associations between zinc status at baseline
and eight measures of cognitive performance were found.
In response to supplementation, only two statistically sig-
nificant effects were observed, namely a temporary
improvement of spatial working memory and an impair-
ment of attention [145].
On the other hand, another recent study with 97 healthy
elderly from Italy, Greece, and Poland found slight bene-
ficial effects of zinc supplementation on cognitive per-
formance, measured by the Mini Mental State
examination, and mood conditions, measured by the ger-
iatric depression scale. Furthermore, it demonstrated an
improvement on the perceived stress scale. Notably, this
latter effect of zinc supplementation was more pro-
nounced in subjects with a certain polymorphism in the
promoter region of the gene for IL-6 [146].
Inflammatory cytokines have been suggested to affect cog-
nitive performance via the production of reactive oxygen
species in brain ageing [147]. Chronic low level inflam-
mation is common in the elderly, and zinc deficiency
impairs cytokine homeostasis in this population, leading
to increased production of pro-inflammatory cytokines
such as IL-6, which can be corrected by zinc supplementa-
tion [70,140]. Taken together, these data suggest that a
supplementation with zinc could act on cognitive and
psychological parameters via modulation pro-inflamma-
tory cytokine levels, although more data to confirm this
hypothesis are certainly required.
Other studies investigated zinc supplementation in com-
bination with additional micronutrients. In a larger study,
725 institutionalized patients (65–103 years) were sup-
plemented for 2 years with zinc sulfate (20 mg zinc)
together with selenium sulfide (100 μg selenium), or mul-
tivitamins, or a combination of both [148]. Patients
treated with selenium and zinc either alone or together
with vitamins, showed higher antibody titers after influ-
enza vaccination, whereas vitamins alone had a negative
effect on response to vaccination. An improvement of
influenza vaccination response by zinc was not confirmed
in another study in which zinc was administered together
with arginine [149], but the relatively high dose of zinc
used in this case (zinc sulfate, 400 mg per day = 90 mg ele-
mental zinc) might have suppressed T cell help.
Although supplementation together with other micronu-
trients makes it difficult to specify the contribution of
zinc, this is possible if appropriate controls are included.
The example of a recent study in Mexican children clearly
demonstrates an effect of zinc supplementation on several
parameters of immune function even if it was adminis-
tered in the presence of other micronutrients [150].
Zinc is generally regarded as a non-toxic essential metal.
Accordingly, correction of zinc deficiency in the elderly
should generally improve the performance of the immune
system, but overdosing zinc supplementation can also
have a negative impact on immune efficiency. In this
respect, two effects are relevant. On the one hand, zinc can
interfere with the uptake of copper. Hence, long-term
high-dose zinc supplementation can lead to severe ane-
mia and neutropenia, based on copper deficiency [151].
On the other hand, pharmacological doses of zinc sup-
press T cell-dependent immune responses [51], and may
cause a temporary reduction of B cell counts [134], lead-
ing to an impaired adaptive immune response when too
much zinc is supplemented.
Conclusion
Zinc ions are indispensable for immune function, espe-
cially for T cell mediated events, which are primarily
affected in immunosenescence. The high prevalence of
zinc deficiency in hospitalized subjects and the correla-
tion between zinc status and immune function surely jus-Page 13 of 17
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Immunity & Ageing 2009, 6:9 http://www.immunityageing.com/content/6/1/9tifies zinc supplementation to these patients to normalize
zinc levels, and hereby restore important functions of the
immune system. One central question remains: Should
the decrease of zinc status with age be seen as a marginal
zinc deficiency, which, in combination with multiple
other factors, increases the susceptibility for infectious dis-
eases and cancer, and should zinc be given to those with
no clinical symptoms? From the results published so far,
it looks like a moderate zinc supplementation that stays
well below the limits for adverse effects could have sub-
stantial benefits. However, a rapid and reliable method
for the assessment of zinc status would be helpful to iden-
tify those who would benefit most from zinc supplemen-
tation.
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